IMMX
Immix Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$481.88M
P/E Ratio
—
EPS
$-0.89
Beta
0.21
52W High
$11.61
52W Low
$1.36
50-Day MA
$8.11
200-Day MA
$4.54
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.71M |
| Operating Margin | 0.00% |
| Return on Equity | -55.00% |
| Return on Assets | -29.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.77 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.01M |
| Float | $36.44M |
| % Insiders | 22.02% |
| % Institutions | 48.35% |
Analyst Ratings
Consensus ($17.56 target)
2
Strong Buy2
BuyData last updated: 4/8/2026